Aurobindo Pharma jumps over 8% on USFDA nod

Shares of Aurobindo Pharma soared over 8 per cent today after the company received final approval from the USFDA to manufacture and market Sevelamer Carbonate tablets.
The scrip of the drug firm surged 8.27 per cent to Rs 794.50 on BSE.
At NSE, shares of the company jumped 8.22 per cent to Rs 794.70.
In terms of volume, 4.63 lakh shares of the company were traded on BSE and over 81 lakh shares changed hands at NSE during morning trading session.
The tablets are indicated for control of serum phosphorus in patients with chronic kidney disease on dialysis.
"The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture Sevelamer Carbonate tablets 800 mg," Aurobindo Pharma said in a BSE filing today.